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ABSTRACT: More than 1,000 Web-based locus-specific
variation databases (LSDBs) are listed on the Website of
the Human Genetic Variation Society (HGVS). These
individual efforts, which often relate phenotype to
genotype, are a valuable source of information for
clinicians, patients, and their families, as well as for
basic research. The initiators of the Human Variome
Project recently recognized that having access to some of
the immense resources of unpublished information
already present in diagnostic laboratories would provide
critical data to help manage genetic disorders. However,
there are significant ethical issues involved in sharing
these data worldwide. An international working group
presents second-generation guidelines addressing ethical
issues relating to the curation of human LSDBs that
provide information via a Web-based interface. It is
intended that these should help current and future
curators and may also inform the future decisions of
ethics committees and legislators. These guidelines have
been reviewed by the Ethics Committee of the Human
Genome Organization (HUGO).
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Introduction
This document is designed to assist a curator who intends to
provide access to the information contained in a human Locus
Specific variation Database (LSDB). For this purpose, an LSDB is
defined as a listing of known sequence variants in a specific
human gene together with some assessment of the effects of these
variants on the phenotype. It may also highlight the frequency of
both common and rare variants (e.g., single nucleotide poly-
morphisms) prevalent in particular populations groups. Although
ethical issues arise in a database of any format, currently the access
is nearly always provided via a Web interface, usually available to
everyone but occasionally restricted to selected professional
groups. An example of a well-known LSDB that can be accessed
by anyone is that describing the mutations in the gene DMD,
deficient in Duchenne Muscular Dystrophy, curated by one of the
authors (J.dD.) in Leiden (http://www.dmd.nl/nmdb2/home.php).
This format is available in open-source software and is now used
in many other LSDBs. The need for these guidelines has been
highlighted by the recognition by initiators of the Human
Variome Project (HVP) of the immense unpublished and
inaccessible resource of information existing in diagnostic
laboratories and the significant clinical need to have access to
this information [Cotton et al., 2007; Kaput et al., 2009].
These guidelines are largely an expansion in detail of the first
generation guidelines proposed by Cotton and coauthors in 2005
[Cotton et al., 2005], which were rooted in the principles
described by Knoppers and Laberge in 2000 [Knoppers and
Laberge, 2000]. They were discussed and modified as a result of
the international HVP planning meeting in Spain May 2008
attended by participants from a wide range of developed and
emerging countries [Kaput et al., 2009]. Details of this can be
found in the published meeting report and its supplementary
information [Kaput et al., 2009]. The content and order of
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et al. [2005] and is shown in Table 1.
Background: Develop a Common Ethical
Framework
The goal of all such databases is the sharing of genomic and
phenotypic information for the benefit of humanity. This requires
the protection of privacy, which in this context is the right of the
individual and members of their family to be protected against
intrusion into their personal information and further intrusions
ensuing from access to this, by publication of information. The
balance between the public’s interest in the value of the shared
information, and its interest in the strict protection of privacy has
been widely discussed. (For example, by the Academy of Medical
Sciences UK in 2006 [http://www.acmedsci.ac.uk/download.php?
file5/images/project/Personal.pdf]; adverse comment in [Matthews,
2007]; UK government report in 2009 on genomic medicine
[http://www.publications.parliament.uk/pa/ld200809/ldselect/ldsctech/
107/10702.htm]; in a commentary from an Islamic perspective [Al
Aqeel, 2007]; from the United States [Taylor, 2008]; and in 2003
from the French National Bioethics advisory Committee [http://
www.ccne-ethique.fr/docs/en/avis076.pdf]).
This balance will be viewed differently in different cultures [Al
Aqeel, 2007] and so international input into detailed guidelines is
essential to ensure collective agreement that is requisite to effective
collaboration. Harmonization of standards will be a challenge.
Although the development of a common ethical framework must
be nurtured by culture and country-specific input, the converse
also holds true: the guidelines will serve as reference for the
developers of national laws and local ethics committees.
For many of the genes and for most of the issues dealt with below it
seems likely that an independent group of well-informed individuals
to oversee specific LSDBs not only at their initiation but on an
ongoing basis will be essential. This general need is underlined by the
2008 revision of the Declaration of Helsinki, http://www.wma.net/en/
30publications/10policies/b3/17c.pdf, which states that monitoring
of ongoing studies must be put in place in addition to the initial
approval by an ethics committee. Governance is thus necessary as
new issues may appear in the course of a project or activity.
Inevitably in these guidelines there is a strong emphasis on the
validity and complexities of consent and the increasing difficulty
of guaranteeing privacy in an era of electronic publishing and
growing internet use. The authors would not wish to discourage
the curation of LSDBs on this account. Current experience of
curators indicates that the majority of patients and research
participants are likely to be happy to share their data, although
inevitably there will be exceptions, and participants’ preference
may change based on new understanding of clinical significance.
So far, curators have been as likely to receive complaints about the
omission of a personal unique variant from the relevant database
as its unexpected inclusion.
Guidelines
The guidelines are presented in approximately the order in
which the issues are encountered by the prospective curator:
Clarify the Main Purpose of the Particular Database,
Recognizing That This may Change Over Time
Who does the curator expect will use this LSDB and why?
This will allow evaluation of the exact information required or
desirable and whether compliance with the remaining guidelines will
be possible with a database open to the public. It may be necessary
to decide that at least part of the information should be restricted to
identified persons. For discussion of robust methods for validation
of identities of enquirers see the GEN2PHEN Knowledge Centre,
http://www.gen2phen.org/researcher-identification-primer.
Many LSDBs are used as a tool by diagnostic laboratories
assessing the likelihood that the DNA change that they have found
is the necessary and sufficient cause of a serious disease and can be
used to inform treatment and/or prevention, including preim-
plantation and prenatal diagnosis and neonatal screening.
However, the data needed will vary in different diseases so even
for this use the ethical issues will be slightly different for each
database. Some examples of questions that must be considered by
curators at this stage are shown in Table 2. The answers will allow
the generation of a list of ethical requirements that any submitter
must fulfil. They will inform decisions about any need for control
of access and may also help in the determination of appropriate
members of an ethical oversight committee as described later.
Both those LSDBs which catalog very rare or even unique
changes relating to serious disease and those that deal with
common variants of small individual effect should adhere to
stringent rules of data standardization, validation, quantification,
and transparency of sources, as described by participants at the
HVP planning meeting [Kaput et al., 2009]. These aims should be
clarified and explained in terms understandable by non specialists
on the public part of the LSDB Website.
Table 1. 12 Major Points to Consider Pertaining to Ethical
Issues Arising in the Curation of Human Locus-Specific Variation
Databases (LSDBs)
1. Clarify the main purpose of the particular database
2. Define database policy with respect to sources of data
3. Take specific communities/cultures into account
4. Take vulnerable persons into account
5. Create an ethics oversight committee
6. Remove identifying information before submission to the database
7. Add further protection of confidentiality if needed
8. Allow no further disclosure without consent
9. Make provision for removal of data from the database
10. Be cautious in response to requests to an LSDB curator for a private opinion
11. Limit links to other LSDBs
12. Consider carefully the transfer of publicly available data from LSDBs to genome
browsers
Table 2. Questions About Aims and Data Required
How much detailed clinical data will be needed and will this be in the form of a link
to another database?
Is any family information needed, for example, to support conclusions on
pathogenicity?
Will an attempt be made to record every apparently unrelated case with the same
mutation?
What ethnic and geographic origin data will be needed and for what purpose?
Will an attempt be made to record all known ‘‘neutral’’ (‘‘normal’’) variation?
Is the aim to evaluate the contribution of common variants to common diseases?
Is the goal to inform basic research into the mechanism of disease, for example,
modifier genes?
Is the aim to evaluate genetic variation in response to therapy in individuals or
populations?
Will the LSDB collect results of in vitro functional analyses?
Will the data include results from a cell or tissue culture of patient/participant
material?
Will the database be used to assemble volunteers for new therapies such as mutation-
specific strategies?
Is the interest mainly from an evolutionary perspective?
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This will be dealt with in two main sections: existing data and
future data, and within each there is a section on data collected for
research and that collected in a diagnostic setting. At the end of
this section we suggest a possible consent form that we propose
might be appropriate in future, particularly for results obtained in
the course of clinical testing.
Existing data
Published data. Usually, information that is already pub-
lished and available electronically is assumed to have been collected
by the appropriate standards that existed at the time of collection.
By virtue of their public availability, these data are generally
assumed to be usable in an LSDB. Although it is possible that the
person giving the consent for the research and publication may not
have foreseen the full implications of Web-based sharing of
information, in most situations the likelihood of reidentification
and/or misuse of data is considered low. Whenever feasible, the
LSDB curator is encouraged to inform the original data producer
(defined as corresponding author for the publication) to explore
whether any restrictions or modifications of data are appropriate.
This recommendation is more for respect of free will and autonomy
of patients than for fear of the risk of reidentification. The
specifics of a particular rare disease may warrant more stringent
monitoring of data; this should be addressed by the ethics oversight
committee of the specific LSDB. The main obligation on the
curator is to check the scientific accuracy as far as possible,
including writing to authors when necessary. Curators should keep
in mind that integration of published data may on occasion give
rise to conclusions with serious implications for individuals or
groups. Similar concerns have been discussed previously, for
example, relating to accumulated data on CGH microarrays [Tabor
and Cho, 2007]. Occasionally discussion with the oversight group
might be needed before full public release of the integrated data.
Data existing in diagnostic laboratories or as clinical
reports. Available but unpublished diagnostic data are a major
problem. This is both because of limited clinical data but also
because current practice does not usually ensure that those
consenting to genetic testing have given permission for sharing
(including scientific publication) of these data beyond the
laboratory and clinical team undertaking the analysis. LSDBs
must be cautious in accepting unpublished data from any
investigators or from accredited diagnostic laboratories, and
consider issues that could limit the clinical accuracy of
unpublished submissions, including standardization of clinical
language, source of data, individual identification, and consent.
It is suggested that where the quality of the data appears to be high
and of significant clinical value but it is not feasible to obtain explicit
consent, the decisions about which data should be uploaded and also
which should be publicly displayed, protected by controlled access or
displayed only in summary form should be made by the independent
LSDB ethical oversight committee (see point 5). This committee must
also be sensitive to different cultural views. In many cases it may be
a p p r o p r i a t ef o rt h e s ed a t at ob ea n o n y m i z e d ,t h a ti s ,m a d e‘ ‘ n o t
identifiable’’ (see point 6 for explanation of ICH sample coding
terminology). Note that the current version of LSDB software LOVD
[Fokkema et al., 2005] has the option to store data that are not public
but that can be queried. The result of a query hitting nonpublic data is
a notification that there is such information in the database but that
the curator needs to be contacted to get more information.
In some cases patients/families already report the data
themselves (often with a copy of the lab result they obtained),
and this can be encouraged with appropriate further information
requested if needed. LSDBs should then have a consent form that
should be signed by the self-submitter and by all relatives whose
results the submitter forwards to the LSDB.
Future data
Research data. In future research projects, consent forms
should specifically indicate what data will be included in a publicly
available database and describe their possible intended uses. The
clinical significance of published data will continue to change as
new findings emerge and the ethical repercussions will depend on
many different variables. It may be appropriate to include
agreement in the original consent about the need for recontact
or for delegation of decision making to an ethical committee for
future unforeseen uses and implications.
Diagnostic data. With regard to consent, we would strongly
recommend that informing donors of the possibility of transmis-
sion of data to an LSDB should in the future be part of the consent
form for all genetic testing, together with an explanation of why
this is useful, and how their privacy will be secured. Refusal to
allow inclusion of data in an LSDB should not affect genetic
testing because this would contravene the traditional commitment
of medicine as exemplified in the UK General Medical Council
guidelines 2006: ‘‘Make the care of your patient your first
concern’’ (http://www.gmc-uk.org/Good_Medical_Practice_0510.
pdf_32611016.pdf).
This should be made clear to the person being asked for
consent. It is essential that this be done without coercion in order
to preserve the freedom of the consent. However, the information
provided to the patients and families should clearly explain the
value of gathering such data and mention that in the long term,
if data cannot be collected, interpretation of testing results may be
less reliable or even impossible, and development of future
possibilities for treatment might be compromised. Although the
curator should require a statement that the submitter has obtained
appropriate consent in whatever way is acceptable in the country
of origin of the data, the primary responsibility is that of the
submitter. The curator should supply to the testing laboratory a
clear explanation about the LSDB on an information sheet that the
laboratory can provide to clinicians and patients.
A suggested form of wording as an addition to the consent for
diagnostic testing (and which may also be appropriate for testing
as part of a research project) is as follows:
a. I understand that the interpretation of DNA test results,
including my own is based mainly on publicly available data
from others who have been tested before me.
b. I agree that the results of my DNA test and clinical
examination may be added to these public data sets, in a
manner that does not disclose my personal identity and that is
in agreement with data protection law in my country.
c. This information will then be available to help the diagnosis of
others, and to further understanding about the disease.
Improved understanding of the molecular mechanisms of
disease may be important in developing new treatments and/
or prevention.
d. Any information that could identify me or members of my
family may only be stored when a high standard of privacy and
confidentiality (as defined and in accordance with national
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tional third-party crossexamination of stored nonidentified data
might indicate, but not prove, identity. Should this happen,
third-party users of the database will undertake not to explore
this information further or to contact me.
e. I understand that I will not receive any payment for this.
This wording will need modification in certain circumstances
and if any part of the interpretation of the result to be shown on
the database depends on family history or testing of other
members of the family, this should be considered and consent
sought if appropriate.
Take Specific Communities/Cultures into Account
Identifiable groups such as Ashkenazi Jews or Roma (Gypsies)
may be particularly affected by a specific disease and thence
become a major part of the relevant LSDB. Following consultation
with the community, every effort must be made to take this into
account and to provide privacy protection and respect cultural
sensitivity ensuring that high ethical standards are maintained.
A small specialized database gives the greatest chance of the
unintended identifiability of one of the subjects. It may
occasionally be necessary to store data only at summary level to
preserve anonymity, as has been done in the Israeli and other
National/Ethnic Mutation Databases (NEMDBs) [Patrinos, 2006;
Zlotogora et al., 2007]. The cultural sensitivity of particular
groups such as the Maori of New Zealand will need a step of local
consultation before any sharing of DNA data, even for disorders
not especially prevalent in that group.
Take Vulnerable Persons into Account
Persons who do not have the capacity to consent either because
of disability or young age are especially vulnerable. In some
disorders, this will apply to many of the patients/ participants and
regular external review of procedures for obtaining consent from
appropriate relatives/representatives or other suitable authority
should be in place. Usually this will be part of the remit of the
LSDB oversight committee.
Create an Ethics Oversight Committee
A variation database that accepts genotype and phenotype data
not already in the public domain (or that are in the public domain
but whose combination and integration are foreseen to change the
degree of identifiability of persons) and makes them widely
available, should have an independent and well-informed over-
sight group. This should be drawn from several disciplines and
from relevant society stakeholders, including patient groups, to
review the particular ethical issues arising in relation to that LSDB.
They should recommend constraints needed in uploading and
displaying data and decide on any requirement for control of
access or for anonymization. The delegation of such decisions to a
committee with a long-term remit will balance the difficulty of
having truly informed consent in such a fast moving field. The
decisions of this committee may require formal ethical approval
either from their own institution or a national body.
A database that only accepts publicly available data would still
benefit from some independent ethical review, and this is strongly
recommended This could be provided either by a specific
oversight committee as described above, or perhaps by an
international HGVS or HVP group who could advise a number
of databases.
Remove Identifying Information Before Submission to
Database
Every effort must be made to ensure that the individuals whose
DNA variation is displayed in an LSDB are not individually
identifiable. With increasing availability of total genomic sequence
and the enormous amount of personal information retrievable
from websites, absolute certainty of nonidentifiability is no longer
guaranteed [Barash, 2007; Homer et al., 2008; Lowrance and
Collins, 2007; Walter, 2007]. However, with care, the risk of
identification from an LSDB will be very low in almost every case,
particularly if data from genome-wide analyses such as single
nucleotide polymorphism (SNP) genotyping data are not
associated with the mutation (see point 7 for possible exceptions
such as unique variants). There is now a set of definitions
including sample coding terminology agreed internationally and
recognized by all constituents of the International Conference
on Harmonisation (ICH) that has become official in 2008
(http://www.fda.gov/downloads/RegulatoryInformation/Guidances/
ucm129296.pdf).
These definitions will be used here and are explained below.
Decide whether data should be ‘‘coded’’ (also called ‘‘reidentifi-
able’’) or ‘‘anonymized’’ (also called ‘‘deidentified’’). For the
purposes of these guidelines, ‘‘coded’’ is taken to mean removal
of all existing identifiers as far as is compatible with usefulness of
the data and substitution by proxy identifiers that are used in the
database. The link between the existing identifier and the proxy
identifier could be maintained either by the submitter acting as the
‘‘honest broker’’ between the hospital records and the LSDB or
within a securely nonpublic area of the LSDB. It would be desirable
that each proxy identifier be unique and generated by a standard
coding mechanism, perhaps by some national or international
body. This would avoid inadvertent duplication of identifiers that
might arise if the process was left to individual LSDB curators. For
published data, and especially for recent publications, many cases
are already coded and then classified as ‘‘reidentifiable’’ specifically
for publication. These codes might be acceptable if not recorded in
hospital notes. However, new coding for the database would be
safer. Unpublished data, unless anonymized as explained below,
should always be recoded to make them reidentifiable and not
directly identifiable. In the case of unpublished data on a rare
disorder it is advisable that no link between a particular entry and
the submitter should be displayed, and that ethnic origin and
geographic data on the donor are not visible. This is recommended
even if the clinical data displayed are minimal.
Anonymized (or ‘‘deidentified’’) here means that identifiers and
any information that might be used as clues to identity through
other links are permanently removed and the link to the ID used by
the submitter is destroyed. This would limit the usefulness of the
data, particularly with regard to long-term phenotype follow-up
data and any late correction of wrong information but also possibly
in ways that cannot currently be predicted. It also makes withdrawal
of consent impossible, and is not the approach of choice.
If the decision is to proceed with coded or in other words
‘‘reidentifiable’’ data, although the original identifier is replaced by
a code, many other pieces of information give possible clues to
identity and will need to be removed to avoid unauthorised
reidentification and, in many countries, to obey privacy laws.
In most published cases, all data given in the publication would be
acceptable to include in the database, including geographical
location and ethnic group of individuals studied (both for cases
and for population controls) and clinical details of patients.
Limited family details present in the original report that help in
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the original publication is acceptable and useful. Note that data on
frequency and population/ethnicity can be very helpful in the
design of cost-effective targeted diagnostics and/or treatment
protocols. For unpublished data, the specific nature of the LSDB
will be considered by the ethical oversight committee in
recommending which data can be collected and displayed. Special
consideration should be given to rare mutations (see point 7).
Add Further Protection of Confidentiality if Needed
This may be necessary in the case of rare or unique mutations
in rare diseases, unique combinations of clinical features, or where
higher protection is required for some other reason. The oversight
committee will be valuable here. The database will have limited
usefulness if important genotype–phenotype data cannot be
released because this information alone might allow identification
of the individual. In diseases where very detailed clinical data
have been collected (especially clinical photographs or detailed
pedigrees) access to these data may have to be restricted by
appropriate registration and approval for access. A possible
solution here that could also be applied to any unpublished data
for which explicit consent is not certain would be to display the
mutation in the database with no other data at all. Someone with
a genuine reason for wanting to know if this mutation causes
disease could then click on a tool that would send an e-mail to the
curator to explore the possibility of finding more information (see
Section 8). There are several variations to this approach and the
display of every variant recorded, including those for which no
other information can be displayed publicly, makes accurate
enquiries easier for the user rather than requiring the enquirer to
specify, in correct format, a variant which is not displayed. As
mentioned in point 2, one of us (J.dD.) has already provided a
similar facility for LOVD databases [Fokkema et al., 2005].
Allow no Further Disclosure Without Consent
Information about a particular entry beyond what is publicly
viewable in the database should not be supplied by a curator to an
enquirer unless consent for this has been explicitly provided. The
request should be referred to the submitter who will use using
professional judgement in their response. This will usually require
seeking further explicit consent from the patient. If there is any
doubt the independent oversight committee should be consulted.
Make Provision for Removal of Data from Database
The parents or guardians who have given consent for a child’s
or incompetent adult’s information to be included in the LSDB
should be made aware of their right to withdraw this information
at any time (unless data are truly not identifiable). The LSDB
should make available information in order to facilitate this task.
If a child reaches the age of consent (16 in many but not all
countries) and is capable of making a decision, those who
previously authorized data sharing should ensure that he/she is
aware of his/her LSDB entry and has the right to withdraw it. This
should also be the case if an adult previously judged incompetent
becomes competent. However, it should be made clear that
although it will be possible to eradicate information that was
originally displayed from the database, it may not be possible to
eradicate it from other sources that have used this information, for
example, in an overview publication.
Be Cautious in Response to Requests to an LSDB Curator
for a Private Opinion
On whether a particular variant is pathogenic, especially if any
of the information used is not published. Add a disclaimer about
responsibility for the clinical use of the opinion and be cautious of
a ‘‘virtual medical advisor relationship.’’ From the medicolegal
point of view, it is safest to obtain clinical interpretation from
published data. If unpublished information is used, a careful
record should be kept. Recommendations of the IARC Working
Group on Unclassified Genetic Variants encourage that classifica-
tion of pathogenicity be carried out not by individuals but by
teams of experts that can carefully evaluate all lines of evidence
[Greenblatt et al., 2008; Tavtigian et al., 2008].
Limit Links to Other LSDBs
If mutations in more than one gene are relevant to a particular
disease, it may be useful to record the variation of both genes in
the same individual and link the entries so that the fact that it is
one person is recorded. This facility is already available on at least
one LSDB platform (LOVD) and can be of great value in the
interpretation of results. However, logically it may eventually
extend to enough genes to allow identification of the individual.
At this point, the considerations of the ethics of large scale
resequencing will be relevant (see [Lowrance and Collins, 2007]).
For example, a recent investigation into DNA variants causing
X-linked mental retardation included substantial amounts of
sequence information on the coding regions of X-linked genes
[Tarpey et al., 2009]. These data were regarded as too sensitive for
the full set of variants for each patient to be entered onto the
LSDBs in the most informative way. See http://www.LOVD.nl/MR
for the summary data submitted.
Consider Carefully the Transfer of Publicly Available Data
from LSDBs to Genome Browsers
Some of the genetic variations collected and displayed by
curators of LSDBs are now visible also in one or several of the
main tools used by scientists worldwide analyzing the human
genome, for example, at the National Center for Bioinformatic
Information (NCBI) at Bethesda, and the UCSC Genome Browser
at Santa Cruz. This does not raise entirely new ethical issues except
in the need for adequate recognition of the work of the LSDB
curator. It makes the misuse of data for reidentification slightly
more likely and may also increase the chance of a mistake being
widely disseminated in a short time. Further discussion of the
sharing of data with genome browsers can be found elsewhere
[den Dunnen et al., 2009].
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